Outcome of Board Meeting

August 5, 2026 BSE Limited, National Stock Exchange of India Limited, Listing Department, P J Towers, Listing Department, "Exchange Plaza", Dalal street, Bandra-Kurla Complex, Bandra (El, Mumbai - 400 001. Mumbai -400 051. scrip Code: 540679 Trading....!ymbol: HALEOSLABS SUB: OUTCOME OF THE 98TH BOARD MEETING. Ref: Regulation 30 and 33 read with Schedule III of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, With reference to the above cited subject, we would like to inform you that the Board of Directors of the Company at their Meeting held today i.e. August 5, 2026, have inter alia considered and approved the following: i. Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, as reviewed and recommended by the Audit Committee and approved by the Board of Directors. In this regard, we are enclosing herewith a copy of un-audited IStandalone and Consolidatedl financial results for the quarter ended June 30, 2026 along with the Limited Review Reports received from the Statutory Auditors of the Company on the said results. ii. Re-appointment of the following Independent Directors for a second term of 5 (five) years with effect from November 13, 2026, subject to approval of the shareholders. SI. NO. Name of Director DIN 1) Dr. (Mr.l Mannam Malakondaiah 01431923 2) Dr. (Mr.l Srinivas Samavedam 02488555 Please note that a detailed report pursuant to sub-para 7 of para "A" of part "A" of Schedule-III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, will be submitted Page 1 of 2 Haleos Labs Limited (Formerly SMS Lifesciences India Limited) Registered & Corporate Office: Plot No. 19-111, Road No 71, Opp Bharatiya Vidya Bhavan Public School. Jubilee Hills, Hyderabad -500 096, Telangana, India. Tel: +91-40-6628 88881C IN -L74930TG2006PLC050223I info~@haleoslabscom I www.haleoslabscom Conti. .. iii. Revision of Managerial Remuneration payable to Mr. TVVSN Murthy, (DIN: 00465198) Managing Director of the Company, subject to approval of the Shareholders. iv. Board's Report for the year ended March 31, 2026. v. Holding the 20th Annual General Meeting on wednesday, September 30,2026, through Video Conferencing ('VC'l/Other Audio Visual Means ('OAVM'l in accordance with General Circular No. 03/2025 dated September 22, 2025 read with General Circular No. 09/2024 dated September 19, 2024 and other applicable MCA Circulars. The above information is also available on the website of the Company at www.haleoslabs.com The meeting of the Board commenced at 12.30 pm and concluded at 01.45 pm. For Haleos Labs Limited ICSI Memb. No. F13407 Page2of2 HALEOS LABS LIMITED (Formerly known as SMS Lifesciences India Limited) (CIN: L74930TG2006PLC050223) Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee hills, Hyderabad -500 096 Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in Standalone Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2026 ( Rs. In Lakhs ) Quarter Ended Year Ended S.No Particulars 30.06.2026 31 03.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) 1 Revenue From Operations 6,782.97 6,338.42 7,904.27 30,098.96 2 Other Income 45.61 9692 10094 142.11 3 Total Revenue 6,828.58 6,43534 8,005.21 30,241 07 4 Expenses (a) Cost of Materials Consumed 3,728.42 3,302.37 3,299.94 14,55749 (b) Changes in Inventories (783.22) (733.80) 540.14 (650.99) (c) Manufacturing Expenses 1,190.00 1,214.04 1,403.78 5,571.54 (d) Employee Benefits Expense 1,324.63 1,206.08 1,249.50 4,939.27 (e) Finance Cost 181.33 133.68 173.27 603.42 (f) Depreciation and Amortization Expense 301.25 265.55 263.45 1,066.40 (g) Other Expenses 358.58 729.66 327.33 1,634,83 Total Expenses -(a to g) 6,300.99 6,117.58 7,257.41 27,721.96 5 Profit Before Tax (3-4) 527.59 317.76 747.80 2,519,11 6 Tax Expenses (1) (i) Current Tax 160.00 (75.00) 225.00 550.00 (ii) Relating to Earlier Year - (17.82) - (17.82) (2) Deferred Tax 43.81 187.12 7.03 209.25 Total Tax Expenses 203.81 94.30 232.03 741.43 7 Net Profit / (Loss) for the Period / Year (5-6) 323.78 223.46 515.77 1,777.68 8 Other Compremensive Income for the Period / Year (OCI): Items that will not be reclassified to profit or Loss: Remeasurement of post-employment benefit obligations 2.75 7.35 1.17 11.03 Income Tax effect on the above 0.80 2.14 0.34 3.21 1.95 5.21 0.83 7.81 9 Total Comprehensive Income for the period / Year (7+8) 325.74 228.67 516.60 1,785.49 10 Earnings Per Equity Share of RS.1 0/-each Basic 1 Diluted (not annualised) 10.71 7.39 17.06 58.80 11 Paid-up equity share capital (Face Value of RS.10/-each) 302.33 302.33 302.33 302.33 12 Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year 21,155.36 HalJ~s For Labs Limited TVVSN MLv-- Managing Director DIN: 00465198 Notes: 1 The above standalone Financial Results have been reviewed and recomended by the Audit Committee on 05th August, 2026 and have been approved by the Board of Directors at its meeting held on 05th August, 2026.The statutory auditors of the Company have carried out limited review of Standalone financial results for the quarter ended 30th June, 2026 and expressed unmodified opinion thereon. 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3 The figures for quarter ended 31st March, 2026 are balancing figures between audited figures of the full financial year ended 31st March, 2026 and the published year to date figures upto third quarter ended 31 st December, 2025, which were subjected to limited review by the auditors. 4 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS1 08. 5 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification. For Hale/s Labs Limited TVVSNMU~ Place: Hyderabad Managing Director Date: 05-08-2026 DIN: 00465198 RAMBABU & CO., CHARTERED ACCOUNTANTS IN 0 I A Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended Review Report to The Board of Directors HALEOS LABS LIMITED (Formerly known as SMS Lifesciences India Limited) We have reviewed the accompanying statement of unaudited standalone financial results of HALEOS LABS LIMITED (Formerly known as SMS Lifesciences India Limited) (" the Company"), for the quarter ended 30th June 2026 ("the statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations"). This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34)" Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express conclusion on the Statements based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial [Showing first 8,000 characters — download PDF for full document]